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ORIGINAL ARTICLE
Randomized, Placebo-Controlled Trial of Low Molecular
Weight Heparin in Active Ulcerative Colitis
M.A. de Bie`vre, MD,* A.A. Vrij, MD,† E.J. Schoon, MD,‡ G. Dijkstra, MD,§ A.E. de Jong, MD,§
A.H. Oberndorff-Klein Woolthuis, MD, H.C. Hemker, MD, and R.W. Stockbru¨gger, MD
Background: In several open and 1 controlled trial, unfractionated
heparin was effective in the treatment of active ulcerative colitis
(UC). Low molecular weight heparin (LMWH) had a similar effect
in several open studies.
Methods: We studied the efﬁcacy, safety, and tolerability of
LMWH in mild to moderately active UC in a randomized, double-
blind, placebo-controlled trial. In all, 29 patients with a mild or
moderate recurrence of UC during salicylate treatment were ran-
domized to receive either reviparin 3,436 IU (n  15) subcutane-
ously twice daily or placebo (n  14). The study period was 8
weeks. Treatment was discontinued if there was no improvement at
4 weeks or at any disease progression. Primary outcome measure
was clinical improvement at 8 weeks measured by the Colitis
Activity Index (CAI) and the Clinical Symptoms Grading (CSG,
based on the CAI). Endoscopic and histologic grading and quality of
life as measured by the Inﬂammatory Bowel Disease Questionnaire
(IBDQ) were secondary outcome measures. Patients were closely
monitored for adverse events.
Results: Twenty of 29 patients ﬁnished the 8-week treatment
period (reviparin versus placebo: 11 versus 9; P  0.70). There was
no difference in CSG, CAI, endoscopic and histologic grading, or
IBDQ. Treatment was well tolerated and no serious adverse events
occurred.
Conclusion: In this study, treatment with LMWH showed no
signiﬁcant clinical advantage compared to placebo in mild to mod-
erately active UC.
(Inﬂamm Bowel Dis 2007;13:753–758)
Key Words: heparin, low molecular weight heparin, ulcerative
colitis, treatment
In the majority of cases the clinical course of ulcerative colitis(UC) is characterized by exacerbations with abdominal pain
and frequent bloody stools, alternating with periods of remis-
sion. The current treatment strategy is aimed at inducing remis-
sion with 5-aminosalicylates (5-ASA) and/or corticosteroids or,
in refractory cases, with cyclosporin or anti-TNF, and main-
taining remission with 5-ASA and/or azathioprine. All these
drugs can have signiﬁcant side effects; also, a proportion of
patients are refractory to them and might require colectomy.
In 1952, in the Netherlands, the ﬁrst article was pub-
lished describing the use of heparin as an anti-inﬂammatory
drug in cases of acute polyarthritis.1 This was followed by a
series of studies from Russia showing some success with
heparin treatment in rheumatoid arthritis.2,3 These results led
to the assumption that there might be a place for the clinical
application of the anti-inﬂammatory properties of heparin. In
1982 a Russian study reported a clinical beneﬁt with unfrac-
tionated heparin (UFH) in patients with active UC.4
In 1991 Gaffney et al5 described 3 patients with active
UC who showed a good response to treatment with UFH; the
ﬁrst of these 3 patients had reported a remission of his colitis
during treatment for a deep vein thrombosis. Successful treat-
ment in a further 6 of 7 patients was reported by the same
group in 1995.6
Subsequently, several studies have been published de-
scribing the treatment of active UC with heparin, mostly in
the UFH form, 2 of which were controlled, comparing hep-
arin to corticosteroids.7,8 The other studies were performed in
an open, uncontrolled manner.9,10 The results varied, with an
overall tendency toward a beneﬁcial effect of UFH. Very few
side effects have been reported. Three studies performed with
low molecular weight heparin (LMWH) also showed beneﬁt,
with clinical improvement rates ranging from 58%–91%.11–13
The treatment was well tolerated. None of these 3 studies,
however, was controlled.
In view of these results we designed a study to test the
hypothesis that LMWH is an effective drug in the treatment
of UC.
MATERIALS AND METHODS
Study Design
We performed a randomized, double-blind, 2-center
trial comparing reviparin (Clivarin, Knoll, Ludwigshafen,
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Germany) 3,436 IU twice daily to placebo in patients with
mild to moderately active UC.
Patient Population
Between August 1996 and February 2000 a total of 29
patients were enrolled at the Departments of Gastroenterol-
ogy of the University Hospitals of Maastricht and Groningen,
The Netherlands. Patients with mild to moderately active UC
(diagnosis based on Lennard-Jones criteria14), with a severity
score of 4–14 according to the Truelove classiﬁcation15 were
eligible. The active colitis could either be the ﬁrst manifes-
tation or an exacerbation of known disease. Sigmoidoscopy
had to have been performed less than 2 weeks before the start
of treatment.
Excluded from the trial were patients with proven
Crohn’s disease, infectious colitis (excluded through stool
cultures), ischemic colitis, or irradiation colitis. Use of oral or
rectal corticosteroids or other immunosuppressive drugs was
prohibited within 4 weeks before study entry. Also excluded
were patients with known thromboembolic disposition or
current use of anticoagulants, patients with known or sus-
pected bleeding tendency, or with regular use of nonsteroidal
anti-inﬂammatory drugs (NSAIDs), including low-dose aspi-
rin. Previous adverse events to heparin therapy, known active
ulcer disease, serious hepatic disease (ASAT 3 upper
limit) or renal failure (serum creatinine 300 mmol/L) as
well as pregnancy or breast feeding in female patients were
other exclusion criteria.
Written informed consent was obtained from all pa-
tients. The protocol was approved by the Ethical Committees
of both participating hospitals.
Treatment
After randomization (random allocation), patients re-
ceived either reviparin (Clivarin, MW 3,900 Da) 3,436 IU
Pharm Eur / 0.6 mL (corresponding to 10,000 U of unfrac-
tionated calcium heparin) subcutaneously or placebo twice
daily. The drug and placebo were made available in individ-
ually packed disposable syringes. Drugs were administered
through self-injection.
All patients were on stable treatment with either sala-
zopyrine (n  4) or mesalazine (n  20) 1 g 2–3 times daily
or olsalazine (n  5) in a comparable dose.
Treatment was intended to last 8 weeks. Control visits
were planned at 1, 2, 4, 6, and 8 weeks. Treatment was
discontinued if there was no improvement after 4 weeks
according to the Clinical Symptom Grading (CSG)16 and/or
Clinical Activity Index (CAI)17 or in any patient with pro-
gression of disease activity at any control visit. Improvement
was deﬁned as a reduction of the CSG and CAI score of more
than 4 points and 6 points, respectively (Tables 1, 2). Other
reasons for discontinuation were heparin-induced thrombo-
cytopenia (HIT) type 218,19 (thrombocytes below 100
 10E9/L) or severe bleeding (deﬁned as hemoglobin [Hb]
5.0 mmol/L, Hb 2.0 mmol/L below baseline value, blood
loss with blood pressure 80/50 mmHg and/or need for
blood transfusion). In patients in whom the study treatment
was discontinued, conventional treatment with corticoste-
roids was initiated.
Outcome Parameters
The primary endpoint of the study was clinical im-
provement after 8 weeks of treatment. Disease activity was
TABLE 1. Colitis Activity Index (CAI)
Symptom Day
Diarrhea x/day Score:
0–2 0
3–4 1
5–6 2
7–9 3
10 4
Diarrhea at night Score:
No 0
Yes 1
Fecal blood loss (%) Score:
0 0
50 1
50 2
100 3
Incontinence for feces Score:
No 0
Yes 1
Abdominal pain Score:
None 0
Mild 1
Moderate 2
Severe 3
General well-being Score:
Perfect 0
Very good 1
Good 2
Moderate 3
Bad 4
Terrible 5
Abdominal tenderness Score:
None 0
Mild, localized 1
Mild to moderate, diffuse 2
Severe or rebound tenderness 3
Antidiarrhea medication Score:
No 0
Yes 1
Total score: (max  21):
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assessed at entry and at every visit by means of the CAI (scale
0–21) and CSG (scale 0–16). Secondary endpoints included
an Endoscopic Grading System16 (EGS; scale 0–18) recorded
at sigmoidoscopy performed before entry and after 8 weeks.
Biopsies were taken at 10 cm from the anus and from the
mid-sigmoid and assessed according to a Histological Grad-
ing System16 (HGS; scale 0–12) by 2 independent patholo-
gists.
Quality of life was assessed at weeks 1, 4, and 8 by
means of the Inﬂammatory Bowel Disease Questionnaire
(IBDQ)20. Safety parameters measured at every visit included
Hb, hematocrit (Ht), white blood count (WBC), platelets,
creatinine, alkaline phosphatase (ALP), aspartate transami-
nase (AST), and alanine transaminase (ALT).
Statistical Methods
The sample size was based on categorical data (“Did
the patient improve?”). For the expected proportion with
speciﬁed outcome: p1  improved on heparin 0.80 (based on
previous uncontrolled studies11–13), p2  improved on pla-
cebo 0.20. The common SD was 0.68. Taking the power to be
0.85 and a 2-sided signiﬁcance level of 0.05, the sample size
was calculated to be 24 for each of the 2 groups.
Analysis was performed on an intention-to-treat basis
with last value carried forward in case of premature discon-
tinuation. The software used was SAS for Windows (v. 6.12;
SAS Institute, Cary, NC). For qualitative parameters (cate-
gorical or ordered), frequency counts and percentages of each
category were calculated by treatment group.
The signiﬁcance of differences between placebo and
LMWH-treated patients was analyzed with the Pearson chi-
square test with asymptotic 2-sided signiﬁcance. For 2  2
tables, Fisher’s exact test was computed. Group mean differ-
ences were calculated using unpaired t-tests for normally
distributed variables or the Mann–Whitney Wilcoxon’s test
for skewed distributed variables.
RESULTS
Patients
Fifteen patients were randomized to receive reviparin
and 14 to receive placebo (19 patients were included in the
University Hospital Maastricht and 10 in the University Hos-
pital Groningen). Demographic data and clinical characteris-
tics of patients randomized to treatment are shown in Table 1.
There was no difference between the 2 groups with regard to
age, gender, or smoking habits. Mean duration and extent of
disease, previous steroid treatment, and individual or family
history of thrombosis or bleeding tendency were similar in
both groups.
Primary Efﬁcacy Endpoint
In the reviparin group 11/15 (73.3%) patients com-
pleted the 8 weeks of treatment and in the placebo group 9/14
(64.3%) (P  0.70). One patient in the placebo group was
lost to follow-up after 2 weeks. In all other patients reason for
discontinuation was either lack of efﬁcacy or exacerbation.
At baseline the mean CAI and CSG levels were not
signiﬁcantly different between the reviparin- and placebo-
treated patient groups (Table 3). At 4 weeks the mean CAI
was 7 (95% conﬁdence interval [CI]: 5–9) in both the revi-
parin and placebo group (P  0.547), and at 8 weeks the
mean CAI was 5 (95% CI: 3–7) in the reviparin group and 6
(95% CI: 3–8) in the patients treated with placebo (P
 0.490) (Fig. 1).
At 4 weeks the mean CSG was 5 (95% CI: 3–7) in both
the reviparin and placebo group (P  0.693), and at 8 weeks
the mean CSG was 4 (95% CI: 1–6) in the reviparin group
and 4 (95% CI: 1–7) in the patients treated with placebo (P
 0.759) (Fig. 2).
TABLE 3. Demographic and Clinical Data at Baseline
Reviparin
(n  15)
Placebo
(n  14) P
Age (yr) 38.0 42.4 NS
Gender
male 9 (60%) 7 (50%) NS
Smoking NS
never 4 2
no 8 11
yes 3 1
Previous corticosteroid
therapy (n) 9 (60%) 9 (64.3%) NS
CAI (min–max) 9.87 (5–16) 9.14 (3–13) NS
CSG (min–max) 8.33 (4–14) 6.36 (2–10) 0.061 (NS)
Mean duration of
disease (yr) (range) 6 (0–15) 7 (0–26) NS
NS, not signiﬁcant.
TABLE 2. Clinical Symptom Grading (CSG)
Parameter/Grade 0 1 2
Blood loss None Sometimes Frequent
Mucus discharge None Sometimes Frequent
Frequency of defecation 3/day 3–6/day 6/day
Consistency of feces Normal Semiliquid Liquid
Tenesmus Absent Mild Severe
Abdominal pain Absent Mild Severe
Rectal pain Absent Mild Severe
Nausea/ vomiting Absent Sometimes Frequent
Maximum score  16.
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Secondary Efﬁcacy Endpoints
The results of the secondary outcome measures are
summarized in Table 4. There were no signiﬁcant differences
in either EGS, HGS, or IBDQ between the groups.
Adverse Events
There were no serious adverse events in either study
group. There was no signiﬁcant difference in adverse events
between the 2 study groups (Table 5).
DISCUSSION
Heparin is a member of the group of glycosaminogly-
cans. Presently, it is mainly used in the treatment and pre-
vention of thromboembolic disorders. Its antithrombotic ac-
tion is achieved through enhancing the activity of
antithrombin III and thus inhibiting hemostasis.
However, several other actions of heparin have been
discovered. In vitro, there is stimulation of several growth
factors, including basic ﬁbroblast growth factor and insulin-
like growth factors.21–24 Additionally, heparin has been
shown to interfere with recruitment, adhesion, and migration
of leukocytes.25,26
Until recently, heparin therapy has mainly consisted of
intravenous application of mixed molecular, unfractionated
heparin (UFH). For most indications this has now been re-
placed by subcutaneous low molecular weight heparin
(LMWH).
Only 1 recent article has been published describing the
effect of LMWH in the treatment of mild to moderately active
TABLE 5. Adverse Events
Reviparin
(n  15)
Placebo
(n  14) P Event
Hematoma on injection site 3 (20%) 2 (14,3%) NS
Liver enzyme elevation 1 (6.7%) 0 NS
Headache 3 (20%) 2 (14.3%) NS
Arthralgia 2 (1.3%) 1 (7.1%) NS
Nausea 3 (20%0 2 (14.3%) NS
Epistaxis 1 (6.7%) 2 (14.3%) NS
NS, not signiﬁcant.
FIGURE 1. Box-Whisker plots of the CAI in reviparin- and
placebo-treated patients at different time intervals, with outli-
ers (0) and extremes (*). No signiﬁcant differences were ob-
served between the 2 groups.
FIGURE 2. Box-Whisker plots of the CSG in reviparin- and
placebo-treated patients at different time intervals, with outli-
ers (0) and extremes (*). No signiﬁcant differences were ob-
served between the 2 groups.
TABLE 4. Endoscopic, Histologic, and Quality of Life
Outcomes
Reviparin Placebo P
EGS
Day 0 (n) 9.64 (14) 9.46 (13) 0.92
Day 57 (n) 7.36 (11) 7.63 (9) 0.80
Patients improved (%) 9 (64.3) 8 (66.7) 0.49
HGS
Day 0 (n) 2.93 (15) 3.93 (14) 0.20
Day 57(n) 2.00 (11) 3.11 (9) 0.33
Patients improved (%) 10 (66.7) 7 (53.4) 0.41
IBDQ
Day 0 132.1 141.2 0.57
Day 57 162.1 173.1 0.71
EGS, Endoscopic Grading System; HGS, Histological Grading System;
IBDQ, Inﬂammatory Bowel Disease Questionnaire.
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UC in a randomized, placebo-controlled manner27 and could
not detect any signiﬁcant advantage. Regarding this, 2 earlier
controlled studies have been reported, both comparing UFH
to corticosteroids. The study by Ang et al8 demonstrated a
similar response rate in both groups, with few side effects in
the UFH group; in contrast, the study performed by Panes et
al7 showed no response in the heparin group and a signiﬁ-
cantly higher rate of rectal bleeding. The disappointing re-
sults of the latter study have been attributed to several factors,
including the lack of concomitant 5-ASA therapy and the
relatively short treatment period of 10 days.30,31 Previous
studies with LMWH11–13 had treatment periods of 8–12
weeks. The administered dose, however, ranged from a low
dose of enoxaparin (5 mg weekly)11 to conventional thera-
peutic doses of daltoparin and nadroparin.12,13 All 3 studies
were uncontrolled. Our study was designed in order to max-
imize the possible effect of the LMWH by continuing the
5-ASA treatment and assuring an adequate duration of treat-
ment. The anticoagulant potency of the dose administered
was comparable to that used by Gaffney et al5,6 in their initial
publications.
Our results show that the treatment was excellently
tolerated but demonstrate no beneﬁcial effect of LMWH in
UC. An important observation in this study is the unexpect-
edly high response in the placebo group of 54%–85% (CSG-
CAI) as compared to 9%–48% in other placebo-controlled
studies in UC.28,29 Possibly this is due to the relatively high
proportion of patients with low disease activity at baseline.
The demographic and clinical characteristics of the patients in
both groups do not offer any other plausible explanation for
this outcome, as they were very similar at baseline.
Several explanations have been suggested for the pos-
sible beneﬁcial effects of heparin in UC. The ﬁnding of
microthrombi in rectal biopsies of patients with UC30 com-
bined with the thrombotic tendency in these patients31 and the
negative correlation between inherited coagulopathies and
inﬂammatory bowel disease32 has led to the theory that the
anticoagulant property of heparin might be the most impor-
tant factor. However, Vrij et al13 found a high rate of clinical
and histologic improvement of inﬂammation, but no signiﬁ-
cant change in microvascular thrombi in patients on LMWH
therapy. Thus, other anti-inﬂammatory mechanisms may be
involved, such as inhibition of leukocyte adhesion to the
vascular endothelium,33 interference with transendothelial
migration of leukocytes through inhibition of neutrophil elas-
tase,34 or stimulation of basic ﬁbroblastic growth factor lead-
ing to improved mucosal repair.21
The current study (as well as the previously mentioned
study by Bloom et al27) has not conclusively shown a major
efﬁcacy of LMWH in the treatment of UC. Most experimen-
tal data are from studies with UFH, which contains a mix of
molecules with a range in molecular weight from 3–30 kD. It
is possible that the anti-inﬂammatory effect of heparin is
mainly achieved by another fraction than the low molecular
one (3–6 kD), in contrast to the anticoagulant effect. Neither
UFH and LMWH appear to be sufﬁciently effective to be
used as monotherapy. Possibly there might be a role for
heparin as adjuvant therapy to corticosteroids with the inten-
tion to delay or even to avoid the need for cyclosporin,
anti-TNF, and/or colectomy.
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